Dacomitinib
An EGFR inhibitor.
General information
Dacomitinib is an EGFR inhibitor used for non-small cell lung cancer treatment (LiverTox).
Dacomitinib on DrugBank
Dacomitinib on PubChem
Dacomitinib on Wikipedia
Marketed as
VIZIMPRO
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2
TMPRSS2 Cathepsin B Cathepsin L Small molecule In silico |
in silico | 6.02 | Predicted to inhibit the host cathepsin B and L proteases and thereby inhibit the SAS-CoV-2 entry. |
Aug/26/2020 |
|
Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
Small molecule In vitro Screening |
Huh7.5 cells; Calu-3 cells; primary normal human bronchial epithelial cells; iPSC-derived AT2 cells; SARS-CoV-2 strain USA WA1/2020 | 8.11 | Inhibited SARS-CoV-2 replication in Huh7.5 cells and also in Calu-3 cells with an SI of >3. |
Mar/23/2021 |
AI-suggested references
| Link | Publication date |
|---|---|
|
Docking and molecular dynamics simulation for therapeutic repurposing in small cell lung cancer (SCLC) patients infected with COVID-19.
|
Apr/10/2020 |
